Bladder cancer is the fifth most common cancer in the United
States - the fourth most frequently diagnosed cancer in men and the
ninth in women. In fact, the American Cancer Society estimates that
there will be more than 63,000 new cases of bladder cancer
diagnosed in the United States in 2005. Accurate and early
diagnosis of bladder cancer is critical to successful treatment.
Inverness Medical Professional Diagnostics offers the first and
only NMP22 ELISA test for the screening and monitoring of this
important disease, the NMP22® Test Kit*,
which detects elevated levels of NMP22 protein in the urine of
patients with bladder cancer, even in the early stages of
disease.
*Manufactured by Matritech, Inc., for Inverness Medical.